首页 | 本学科首页   官方微博 | 高级检索  
检索        

特立帕肽致不良反应文献分析
引用本文:赵俊,徐文,倪倍倍,张传洲,李祥鹏,郭切,隋忠国.特立帕肽致不良反应文献分析[J].中国医院药学杂志,2021,41(12):1249-1254.
作者姓名:赵俊  徐文  倪倍倍  张传洲  李祥鹏  郭切  隋忠国
作者单位:青岛大学附属医院药学部, 山东 青岛 266003
基金项目:山东省自然科学基金项目(编号:ZR2019MH077)、青岛大学附属医院青年科研基金项目(编号:QDFY201919)
摘    要:目的: 探讨特立帕肽致不良反应(ADRs)的规律和特点,为临床安全用药提供参考。方法: 检索2002年1月-2020年12月PubMed、Web of Science、Springer Link、中国知网(CNKI)、万方数据知识服务平台及维普数据库中特立帕肽致不良反应的病例报道,对纳入文献的有效信息进行提取并分析。结果: 特立帕肽ADRs病例报道11篇共14例,其中男2例(14.29%)、女12例(85.71%),60岁以上发生ADRs的患者11例(78.57%),合并基础疾病13例(92.86%);注射特立帕肽1 d内发生ADRs者3例(21.43%),1~6个月内发生ADRs者8例(57.14%),患者经停药及对症处理后症状均好转。1例(7.14%)出现无症状短暂低血压的患者继续使用特立帕肽,其余均未再次使用特立帕肽。ADRs主要表现为皮肤及附件损害4例(28.57%),肌肉骨骼系统损害和生化指标异常各3例(均为21.43%),心血管系统损害2例(14.29%),肿瘤和全身性损害各1例(均为7.14%)。结论: 特立帕肽致ADRs的特点是女性和60岁以上老年人占比较高,多数患者合并多种基础疾病,发生的ADRs主要涉及皮肤及附件损害、肌肉骨骼系统损害、生化指标异常等,大部分患者经停药及对症治疗后症状好转或痊愈。临床使用特立帕肽时应严格按照说明书合理用药,加强用药监护及教育,警惕ADR发生。

关 键 词:特立帕肽  重组人甲状旁腺激素  不良反应  文献分析  
收稿时间:2021-01-21

Literature analysis of adverse reactions induced by teripartide
ZHAO Jun,XU Wen,NI Bei-bei,ZHANG Chuan-zhou,LI Xiang-peng,GUO Qie,SUI Zhong-guo.Literature analysis of adverse reactions induced by teripartide[J].Chinese Journal of Hospital Pharmacy,2021,41(12):1249-1254.
Authors:ZHAO Jun  XU Wen  NI Bei-bei  ZHANG Chuan-zhou  LI Xiang-peng  GUO Qie  SUI Zhong-guo
Institution:Department of Pharmacy, Affiliated Hospital of Qingdao University, Shandong Qingdao 266003, China
Abstract:OBJECTIVE To explore the regularity and characteristics of adverse reactions (ADRs) caused by teripartide and provide references for clinical safe drug dosing.METHODS Case reports of adverse reactions caused by teripartide were retrieved from the databases of PubMed, Web of Science, SpringerLink, China National Knowledge Network (CNKI), WanFang Data Knowledge Service Platform and VIP from January 2002 to December 2020.And the relevant information of included literatures was extracted.RESULTS A total of 14 cases of teripartide ADRs were collected from 11 reports.There were 2 males (14.29%) and 12 females (85.71%).ADRs occurred in 11 patients aged over 60 years (78.57%) and 13 patients (92.86%) with underlying diseases.ADRs occurred in 3 patients (21.43%) within 1 day and in 8 patients (57.14%) within 1-6 months after dosing of teripartide.All symptoms improved or recovered after drug withdrawal and symptomatic treatment.One patient (7.14%) with asymptomatic transient hypotension continued to receive teriparin while the remainder withdrew teriparin.The major manifestations of ADRs were skin & accessory lesions (n=4, 28.57%), musculoskeletal system lesions (n=3, 21.43%, both), cardiovascular system lesions (n=2, 14.29%, both) and tumor and systemic lesions (n=1, 7.14%, both).CONCLUSION ADRs caused by teripartide are characterized by a high proportion of females and elders aged over 60 years.Most patients are complicated with a variety of underlying diseases and ADRs mainly involve skin and accessory damage, musculoskeletal system lesions and abnormal biochemical parameters.Most symptoms improve or patients become cured after drug withdrawal and symptomatic treatment.Teripartide should be strictly administered through following the instructions of rational drug dosing, strengthening drug monitoring & tutoring and alerting to the occurrence of ADR.
Keywords:teriparatide  recombinant human parathyroid hormone  adverse reaction  Literature analysis  
点击此处可从《中国医院药学杂志》浏览原始摘要信息
点击此处可从《中国医院药学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号